PCOS Is Now PMOS - Poly-endrocrine metabolic ovary syndrome
By Dr. Amina Hersi
Last week, one of the most common yet misunderstood conditions affecting women officially got a new name.
PCOS — Polycystic Ovary Syndrome — is now PMOS: Polyendocrine Metabolic Ovary Syndrome.
And whether people love the new name or hate it, one thing is clear:
Medicine is finally acknowledging that this condition was never just about ovaries.
The announcement followed a 14-year international consensus process involving expert panels, working groups, and ongoing debate around whether the old name still reflected current scientific understanding of the condition.
The reaction online was immediate.
Supportive threads. Angry threads. Confused threads. Women who had only just become comfortable saying “PCOS” suddenly being told the acronym had shifted underneath them.
And honestly, all of those reactions make sense.
As a women’s health doctor, I wanted to write something more useful than a press release summary or a viral hot take.
Because there are good reasons behind the PMOS rename.
There are also real problems with how this transition is happening.
And there is one part of the story that I think deserves far more attention than it is currently getting.
_____________________________________________________________________________
What does PMOS stand for?
PMOS stands for Polyendocrine Metabolic Ovary Syndrome.
The new terminology replaces “Polycystic Ovary Syndrome” (PCOS), a name that shaped decades of research, clinical guidelines, public awareness, and patient identity.
And the shift is significant.
Because the new name explicitly recognises that this condition is not simply reproductive.
It is endocrine.
It is metabolic.
It is systemic.
For years, many women with PCOS felt trapped between two narratives:
Either their condition was reduced entirely to fertility.
Or it was reduced entirely to weight.
Neither reflected the full biological complexity of what patients were actually experiencing.
The exhaustion.
The energy crashes.
The cravings.
The skin changes.
The mood fluctuations.
The feeling that your body was operating on a completely different set of instructions.
The PMOS rename is effectively medicine acknowledging that this condition extends far beyond ovarian ultrasound findings alone.
_____________________________________________________________________________
The Good
1. The metabolic reality of the condition is now impossible to ignore
This is probably the most important shift behind the PMOS rename.
For decades, PCOS largely sat inside the reproductive health category. That framing shaped everything from research funding to referral pathways to how seriously the condition was taken outside fertility settings.
But hormonal health does not exist in isolation from metabolic health.
The body’s signalling systems constantly interact with one another: ovarian function, insulin signalling, androgen pathways, inflammatory signalling, appetite regulation, adipose tissue, liver metabolism, and brain signalling all overlap.
The new PMOS framing places metabolism and endocrinology directly into the name itself.
That matters.
For patients, this may sound like semantics.
For researchers applying for grants, hospital departments deciding ownership of care pathways, and pharmaceutical companies deciding where investment goes, it absolutely is not.
Importantly, recognising PMOS as a metabolic condition does not mean every patient fits one body type.
Metabolic dysfunction can exist across the weight spectrum, including in lean women who are often overlooked or diagnosed later because they do not fit the stereotypical presentation associated with PCOS.
That nuance has historically been poorly communicated in mainstream conversations around the condition.
2. The old name was medically misleading
The word “polycystic” caused confusion for decades.
The follicles visible on ultrasound in PMOS are not ovarian cysts in the traditional clinical sense.
Many women were incorrectly told they could not have PCOS because they did not have “cysts” visible on imaging. Others were unnecessarily alarmed about ovarian cyst complications unrelated to their diagnosis.
The old terminology often simplified an extraordinarily complex condition into one ultrasound finding.
Removing that language is scientifically more accurate.
At the same time, I understand why some women feel emotionally conflicted about the change.
For many patients, ovarian imaging was the first visible confirmation that something was genuinely wrong. It gave shape to symptoms they may have spent years being dismissed over.
When the language changes, it can feel destabilising.
Both things can be true simultaneously:
- the rename is medically more accurate
- the emotional adjustment for patients is real
_____________________________________________________________________________
3. Female-specific biology remained central
This point deserves more attention than it is receiving.
There were earlier discussions around terminology that could have removed ovarian specificity from the name entirely.
The consensus group ultimately retained ovary-specific biology as central to the diagnosis.
Initially, I was not convinced that keeping “ovary” in the name was the right decision. Part of me felt it continued reinforcing the idea that this condition exists primarily through the lens of fertility and reproduction, when many women experience it as something far broader and more systemic than that.
But ultimately, I think retaining ovarian specificity was the correct call.
Because research pools matter.
Had the condition been renamed in a way that also encompassed similar metabolic presentations seen in men, there is a real possibility that future research cohorts would begin blending male and female data within a condition where sex-specific hormonal physiology is fundamental.
Women’s health research is already underpowered relative to prevalence. Diluting female-specific data further would not have strengthened the science. It would have weakened it.
_____________________________________________________________________________
The Bad
The communication gap is real — and it is being underestimated
Right now, millions of women globally have a PCOS diagnosis documented across:
- GP records
- hospital letters
- fertility referrals
- insurance documents
- prescriptions
- online support groups
And overnight, the language changed.
The problem is that the infrastructure surrounding that change has not caught up yet.
What happens when someone Googles PMOS and finds limited patient-friendly information?
What happens when patients ask frontline clinicians about PMOS before those clinicians have fully integrated the terminology themselves?
What happens when newly diagnosed women feel confused about whether they still “have PCOS”?
These are not minor issues.
They are clinical governance issues.
Historically, medicine has not always handled large-scale terminology transitions particularly well from a patient communication perspective, and I do not yet see strong evidence that this rollout will be substantially different without pressure from patient advocates.
If you currently have a PCOS diagnosis, the important thing to understand is this:
Your condition has not suddenly changed.
Your biology has not changed.
Your symptoms are valid.
The terminology changed. The underlying condition did not.
Experts are now recommending that medical professionals use the phrasing:
“PMOS (previously known as PCOS)”
during this transition period to reduce patient confusion and maintain continuity across medical records, referrals, prescriptions, and public health communication.
This transitional phase is expected to continue until at least 2028 as healthcare systems, clinical guidelines, educational materials, research databases, and patient-facing resources gradually adopt the new terminology.
That may sound administrative, but for patients it matters enormously.
Medical language shapes how people search for information, access support groups, understand their diagnosis, and advocate for themselves within healthcare systems.
Without a coordinated transition strategy, there is a genuine risk that patients temporarily fall into an information gap between two names describing the same condition.
_____________________________________________________________________________
The Ugly
Africa and Asia were underrepresented in the process
This is the part of the PMOS discussion I believe is being significantly under-discussed.
PMOS disproportionately affects women of South Asian, Middle Eastern, and African backgrounds, often with more severe metabolic features, higher rates of insulin resistance, and earlier onset of associated complications.
Yet the consensus structures behind the rename appear to have been heavily weighted toward Western European and North American institutions.
That is not a minor procedural detail.
The populations most affected by the condition were underrepresented in a 14-year process that ultimately reshaped how the condition is named, framed, researched, and communicated globally.
There is a version of this process that could have centred the populations carrying the greatest disease burden.
That version may still have arrived at PMOS.
But the legitimacy of the process would have felt very different.
Women’s health has spent decades being underfunded, under-researched, and poorly prioritised relative to prevalence.
Getting the governance of its own renaming process wrong feels like a missed opportunity that deserves to be acknowledged honestly.
_____________________________________________________________________________
Where this leaves us
The PMOS rename is not just about language.
It reflects a broader shift in how medicine understands the condition itself.
For years, many women intuitively understood that their symptoms extended beyond reproductive health alone.
Research is finally beginning to catch up with that reality.
The direction of travel — toward recognising PMOS as a metabolic and endocrine condition rather than purely a reproductive one — is scientifically important.
But renaming a condition does not automatically improve outcomes.
Better research does.
Better representation does.
Earlier diagnosis does.
Doctors who understand the metabolic complexity of the condition do.
The name is the easy part.
What follows it is where the real work begins.
Share:
0 comments
Blog posts
-
Cortisol: getting to know public enemy number one.
Cortisol has become the internet’s favourite hormone to blame. But is cortisol really the problem, or is chronic stress the bigger issue? In this article, we explore what cortisol actually does, the difference between true medical conditions like Cushing’s syndrome and Addison’s disease, the relationship between stress and magnesium, and why the wellness industry’s obsession with “lowering cortisol” may be oversimplifying women’s health. We also examine the rise of adaptogens like ashwagandha and rhodiola, and the lack of robust research in premenopausal women.
-
PCOS Is Now PMOS - Poly-endrocrine metabolic ovary syndrome
PCOS has officially been renamed PMOS: Polyendocrine Metabolic Ovary Syndrome. After 14 years of international debate, medicine is finally acknowledging that this condition was never just about ovaries. In this article, women’s health doctor Amina Hersi breaks down the good, the bad, and the uncomfortable reality behind the PMOS rename — from metabolic recognition and research funding to patient confusion, representation, and why Africa and Asia being underrepresented in the process matters more than most headlines are acknowledging.
-
Your 8 Hours is Not His 8 Hours: The Science of Women and Sleep
Women need more sleep than men, experience it differently, and pay a heavier price when they do not get enough. A clinical breakdown of what sleep does for the female body, why poor sleep hits harder for women, and practical changes you can make tonight.
